Terms: = Colorectal cancer AND CTLA4, ALPS5, CD, CD152, CELIAC3, CTLA-4, GRD4, GSE, IDDM12 AND Treatment
456 results:
1. Clinical Phenotype and Disease Course of Inflammatory Bowel Disease in Iran: Results of the Iranian Registry of Crohn's and Colitis (IRCC).
Saberzadeh-Ardestani B; Khosravi AA; Mansour-Ghanaei F; Vahedi H; Baniasadi N; Seyyedmajidi M; Parhizkar B; Hormati A; Naghshbandi SJ; Matin S; Hassan Zadeh AA; Taghvaei T; Bahrami M; Rafeey M; Ahadi M; Vossoughinia H; Muosavi H; Gheibi S; Hosseini-Hemmatabadi RS; Yazdanbod A; Matinkhah S; Sheikh Esmaeili F; Fakheri H; Moosavy SH; Maleki I; Nasseri-Moghaddam S; Khosravi B; Farahmand F; Najafi M; Alimadadi H; Malekzadeh M; Anushiravani A; Kasaeian A; Alatab S; Sadeghi A; Radmard AR; Kolahdoozan S; Rajabi Z; Sima AR
Arch Iran Med; 2024 Apr; 27(4):183-190. PubMed ID: 38685844
[TBL] [Abstract] [Full Text] [Related]
2. Molecular insights into clinical trials for immune checkpoint inhibitors in colorectal cancer: Unravelling challenges and future directions.
Sharma S; Singh N; Turk AA; Wan I; Guttikonda A; Dong JL; Zhang X; Opyrchal M
World J Gastroenterol; 2024 Apr; 30(13):1815-1835. PubMed ID: 38659481
[TBL] [Abstract] [Full Text] [Related]
3. Binimetinib in combination with nivolumab or nivolumab and ipilimumab in patients with previously treated microsatellite-stable metastatic colorectal cancer with RAS mutations in an open-label phase 1b/2 study.
Elez E; Cubillo A; Alfonso PG; Middleton MR; Chau I; Alkuzweny B; Alcasid A; Zhang X; Van Cutsem E
BMC Cancer; 2024 Apr; 24(1):446. PubMed ID: 38600471
[TBL] [Abstract] [Full Text] [Related]
4. [Expression of immune checkpoints PD-L1, ctla4, LAG3 in the microenvironment of colon adenocarcinoma depending on MMR status].
Naumov SS; Krakhmal NV; Tashireva LA; Vtorushin SV
Arkh Patol; 2024; 86(2):6-13. PubMed ID: 38591901
[TBL] [Abstract] [Full Text] [Related]
5. Tumor microenvironment reprogramming combined with immunogenic enhancement by nanoemulsions potentiates immunotherapy.
Shen W; Li Y; Yang Z; Li W; Cao Y; Liu Y; Wang Z; Pei R; Xing C
J Nanobiotechnology; 2024 Apr; 22(1):154. PubMed ID: 38581017
[TBL] [Abstract] [Full Text] [Related]
6. Unveiling the immune symphony: decoding colorectal cancer metastasis through immune interactions.
He R; Huang S; Lu J; Su L; Gao X; Chi H
Front Immunol; 2024; 15():1362709. PubMed ID: 38415252
[TBL] [Abstract] [Full Text] [Related]
7. Clinical factors associated with severity in patients with inflammatory bowel disease in Brazil based on 2-year national registry data from GEDIIB.
Fróes RSB; Andrade AR; Faria MAG; de Souza HSP; Parra RS; Zaltman C; Dos Santos CHM; Bafutto M; Quaresma AB; Santana GO; Luporini RL; de Lima Junior SF; Miszputen SJ; de Souza MM; Herrerias GSP; Junior RLK; do Nascimento CR; Féres O; de Barros JR; Sassaki LY; Saad-Hossne R
Sci Rep; 2024 Feb; 14(1):4314. PubMed ID: 38383742
[TBL] [Abstract] [Full Text] [Related]
8. Neoadjuvant Immunotherapy With Ipilimumab Plus Nivolumab in Mismatch Repair Deficient/Microsatellite Instability-High colorectal cancer: A Preliminary Report of Case Series.
Pan T; Yang H; Wang WY; Rui YY; Deng ZJ; Chen YC; Liu C; Hu H
Clin Colorectal Cancer; 2024 Mar; 23(1):104-110. PubMed ID: 38336555
[TBL] [Abstract] [Full Text] [Related]
9. [A Case of Clostridium difficile Enteritis with Ileostomy for Rectal cancer Surgery].
Takahashi H; Hamasaki S; Tanaka H; Sakamoto Y; Kawasaki R; Mitsui N; Morikita T; Oda H
Gan To Kagaku Ryoho; 2023 Dec; 50(13):1647-1649. PubMed ID: 38303370
[TBL] [Abstract] [Full Text] [Related]
10. Engineering tumor-colonizing E. coli Nissle 1917 for detection and treatment of colorectal neoplasia.
Gurbatri CR; Radford GA; Vrbanac L; Im J; Thomas EM; Coker C; Taylor SR; Jang Y; Sivan A; Rhee K; Saleh AA; Chien T; Zandkarimi F; Lia I; Lannagan TRM; Wang T; Wright JA; Kobayashi H; Ng JQ; Lawrence M; Sammour T; Thomas M; Lewis M; Papanicolas L; Perry J; Fitzsimmons T; Kaazan P; Lim A; Stavropoulos AM; Gouskos DA; Marker J; Ostroff C; Rogers G; Arpaia N; Worthley DL; Woods SL; Danino T
Nat Commun; 2024 Jan; 15(1):646. PubMed ID: 38245513
[TBL] [Abstract] [Full Text] [Related]
11. Targeting the NAT10/NPM1 axis abrogates PD-L1 expression and improves the response to immune checkpoint blockade therapy.
Qin G; Bai F; Hu H; Zhang J; Zhan W; Wu Z; Li J; Fu Y; Deng Y
Mol Med; 2024 Jan; 30(1):13. PubMed ID: 38243170
[TBL] [Abstract] [Full Text] [Related]
12.
Battaglin F; Baca Y; Millstein J; Yang Y; Xiu J; Arai H; Wang J; Ou FS; Innocenti F; Mumenthaler SM; Jayachandran P; Kawanishi N; Lenz A; Soni S; Algaze S; Zhang W; Khoukaz T; Roussos Torres E; Seeber A; Abraham JP; Lou E; Philip PA; Weinberg BA; Shields AF; Goldberg RM; Marshall JL; Venook AP; Korn WM; Lenz HJ
J Immunother Cancer; 2024 Jan; 12(1):. PubMed ID: 38212126
[TBL] [Abstract] [Full Text] [Related]
13. An overview of up-and-coming immune checkpoint inhibitors for pancreatic cancer.
Mahadevia H; Uson Junior PLS; Wang J; Borad M; Babiker H
Expert Opin Pharmacother; 2024; 25(1):79-90. PubMed ID: 38193476
[TBL] [Abstract] [Full Text] [Related]
14. [Inflammatory bowel diseases: Transformation of representations. A review].
Maev IV; Bakulin IG; Skalinskaya MI; Skazyvaeva EV
Ter Arkh; 2023 Dec; 95(12):1064-1074. PubMed ID: 38158940
[TBL] [Abstract] [Full Text] [Related]
15. Serum concentrations of proinflammatory biomarker interleukin-6 (IL-6) as a predictor of postoperative complications after elective colorectal surgery.
Procházka V; Lacina L; Smetana K; Svoboda M; Skřivanová K; Beňovská M; Jarkovský J; Křen L; Kala Z
World J Surg Oncol; 2023 Dec; 21(1):384. PubMed ID: 38098074
[TBL] [Abstract] [Full Text] [Related]
16. Sustained Disease Control in Immune Checkpoint Blockade Responders with Microsatellite Instability-high colorectal cancer after treatment Termination.
Simmons K; Thomas JV; Ludford K; Willis JA; Higbie VS; Raghav KPS; Johnson B; Dasari A; Kee BK; Parseghian CM; Lee MS; Le PH; Morelli MP; Shen JP; Bent A; Vilar E; Wolff RA; Kopetz S; Overman MJ; Morris VK
Cancer Res Commun; 2023 Dec; 3(12):2510-2517. PubMed ID: 38085001
[TBL] [Abstract] [Full Text] [Related]
17. Single protein encapsulated SN38 for tumor-targeting treatment.
Yu C; Huang F; Wang K; Liu M; Chow WA; Ling X; Li F; Causey JL; Huang X; Cook-Wiens G; Cui X
J Transl Med; 2023 Dec; 21(1):897. PubMed ID: 38072965
[TBL] [Abstract] [Full Text] [Related]
18. Is an uncomplicated postoperative recovery following total pelvic exenteration a more important prognostic factor than achieving R0 in the first 2 years?
Ralston C; Hainsworth A; de Naurois J; Schizas A; George M
Colorectal Dis; 2024 Jan; 26(1):73-80. PubMed ID: 38071402
[TBL] [Abstract] [Full Text] [Related]
19. Targeting ctla-4: a possible solution for microsatellite-stable colorectal cancer.
Ghiringhelli F; Thibaudin M
Genes Immun; 2023 Dec; 24(6):283-284. PubMed ID: 38066340
[TBL] [Abstract] [Full Text] [Related]
20. Chemokine- and chemokine receptor-based signature predicts immunotherapy response in female colorectal adenocarcinoma patients.
Zhu W; Wu C; Hu S; Liu S; Zhao S; Zhang D; Qiu G; Cheng X; Huang J
Sci Rep; 2023 Dec; 13(1):21358. PubMed ID: 38049474
[TBL] [Abstract] [Full Text] [Related]
[Next]
